AVROBIO Inc. (AVRO) deprioritizing its Fabry disease program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Avrobio Inc. (AVRO) PT Lowered to $6 at Mizuho Securities
January 5, 2022 5:28 PM ESTMizuho Securities analyst Uy Ear lowered the price target on Avrobio Inc. (NASDAQ: AVRO) to $6.00 (from $28.00) while maintaining a Buy rating.
The analyst commented, "The new clinical data from the Fabry program is disappointing. We update our model to exclude our sales and... More
AVROBIO's (AVRO) Focus Shift is Disappointing, But Logical, Outlook is Cautions - Stifel
January 4, 2022 10:37 AM ESTStifel analyst Dae Gon Ha maintains a "Hold" rating on shares of AVROBIO Inc. (NASDAQ: AVRO), following news that company is shifting its portfolio... More
AVROBIO Inc. (AVRO) Halted, News Pending
January 4, 2022 6:55 AM ESTAVROBIO Inc. (NASDAQ: AVRO) Halted, News Pending
